<?xml version="1.0" encoding="iso-8859-1" ?>
<rss version="2.0" xmlns:s="http://resources.bnet.com/">
<channel>
	<title><![CDATA[Cephalon Inc. | Company News & Executive Profiles - CEPH | BNET]]></title>
	<link><![CDATA[http://resources.bnet.com/topic/cephalon+inc..html?i=11]]></link>
	<description><![CDATA[Latest company news & analysis, recent events, stock quotes, earning call transcripts, with profiles and descriptions of top business executives for Cephalon Inc.]]></description>
	<s:counts start="0" returned="10" found="175" />
	<language>en-us</language>
	<item>
		<title><![CDATA[Cephalon Q3 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-357574.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Thank you. operator instructions Our first question comes from Jim Birchenough. Jim Birchenough - Barclays Capital Yeah hi guys. Couple of questions on the pipeline. Just on reslizumab, can you give us any details on what percent of patients are going into the open label extension phase...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 27 Oct 2009 18:54:09 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/label.html"><![CDATA[Label]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/question.html"><![CDATA[Question]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="tickers">CEPH</category>
	</item>
	<item>
		<title><![CDATA[Generics Threaten Drugmaker Cephalon's Success]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004361/generics-threaten-drugmaker-cephalons-success/]]></link>
		<description><![CDATA[  Biotechnology watchers are measuring success at Cephalon on how quickly the drugmaker can convert patients on its soon-to-go generic blockbuster Provigil to regular users of its narcoleptic successor Nuvigil. As Jim Edwards at BNET Pharma astutely pointed out exactly one year ago, however, competition also threatens to derail...]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Mon, 21 Sep 2009 08:38:56 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/biotechnology+watcher.html"><![CDATA[Biotechnology Watcher]]></category>
		<category domain="http://resources.bnet.com/topic/provigil.html"><![CDATA[Provigil]]></category>
		<category domain="http://resources.bnet.com/topic/nuvigil.html"><![CDATA[Nuvigil]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/david+phillips.html"><![CDATA[David Phillips]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="tickers">CEPH</category>
	</item>
	<item>
		<title><![CDATA[Suit Claims Cephalon's Actiq Is Fatal to Teeth]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10004145/suit-claims-cephalons-actiq-is-fatal-to-teeth/]]></link>
		<description><![CDATA[Cephalon developed a sugar-free version of its Actiq fentanyl painkiller lollipop but chose not to market it, despite reports from patients that the sugar in Actiq was rotting their teeth, a man alleges in a state court case in Texas. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Tue, 08 Sep 2009 14:24:56 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="tickers">CEPH</category>
	</item>
	<item>
		<title><![CDATA[Cephalon Q2: Not Taking Nuvigil to Stay Awake Yet? You Will Be, Company Believes]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10003496/cephalon-q2-not-taking-nuvigil-to-stay-awake-yet-you-will-be-company-believes/]]></link>
		<description><![CDATA[Cephalon is in the middle of a titanic struggle to move as many patients off its Provigil wakefulness drug onto its new brand, Nuvigil, which it just launched. Provigil goes off-patent sometime between now and April 2012, sooner if the FTC prevails in its anti pay-for-delay suit against the company....]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Thu, 06 Aug 2009 11:38:41 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/provigil.html"><![CDATA[Provigil]]></category>
		<category domain="http://resources.bnet.com/topic/branding.html"><![CDATA[Branding]]></category>
		<category domain="http://resources.bnet.com/topic/marketing.html"><![CDATA[Marketing]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="tickers">CEPH</category>
	</item>
	<item>
		<title><![CDATA[Cephalon, Inc. Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://www.bnet.com/2462-14055_23-328352.html]]></link>
		<description><![CDATA[ Question-and-Answer SessionOperator Operator Instructions We'll go first to Eric Schmidt with Cowen and Company. Eric Schmidt - Cowen and Company Frank, on TREANDA, I think you mentioned that NHL now is the primary driver of growth taking over from CLL a quarter ago. Yet on a quarter-over-quarter basis there...]]></description>
		<s:doctype><![CDATA[Earnings calls]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 04 Aug 2009 19:08:14 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/growth.html"><![CDATA[Growth]]></category>
		<category domain="http://resources.bnet.com/topic/call+transcript.html"><![CDATA[Call Transcript]]></category>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/earnings.html"><![CDATA[Earnings]]></category>
		<category domain="http://resources.bnet.com/topic/nhl.html"><![CDATA[NHL]]></category>
		<category domain="http://resources.bnet.com/topic/cll.html"><![CDATA[CLL]]></category>
		<category domain="http://resources.bnet.com/topic/seeking+alpha.html"><![CDATA[Seeking Alpha]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="tickers">CEPH</category>
	</item>
	<item>
		<title><![CDATA[Cephalon: Bullish Potential]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F153646-cephalon-bullish-potential%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[optionMONSTER submits:  By Bryan McCormick Ahead of Cephalon's earnings report after today's market close, there are some interesting technical features and other factors worth noting in the name. by optionMONSTER]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 04 Aug 2009 11:00:33 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/optionmonster.html"><![CDATA[optionMONSTER]]></category>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="tickers">CEPH</category>
	</item>
	<item>
		<title><![CDATA[Cephalon, Inc. Q2 2009 Earnings Call Transcript]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F153789-cephalon-inc-q2-2009-earnings-call-transcript%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Cephalon, Inc. CEPH   Q2 2009 Earnings Call   August 4, 2009 5:00 pm ET]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 04 Aug 2009 08:08:14 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/biotech.html"><![CDATA[Biotech]]></category>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="tickers">CEPH</category>
	</item>
	<item>
		<title><![CDATA[Cephalon's Nuvigil Test Included "Vacation" in France]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002938/cephalons-nuvigil-test-included-vacation-in-france/]]></link>
		<description><![CDATA[Cephalon will ask the FDA to approve its sleep drug Nuvigil for "Eastbound" jet lag. Not Westbound. Eastbound, the company says. Turns out Cephalon flew 427 adults from the East Coast of the U.S. to France to test the drug. by Jim Edwards]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Wed, 01 Jul 2009 10:17:36 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/federal+government.html"><![CDATA[Federal Government]]></category>
		<category domain="http://resources.bnet.com/topic/government.html"><![CDATA[Government]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="tickers">CEPH</category>
	</item>
	<item>
		<title><![CDATA[The FTC's Pay-for-Delay Threat: It's All Cephalon CEO Baldino's Fault]]></title>
		<link><![CDATA[http://industry.bnet.com/pharma/10002848/the-ftcs-pay-for-delay-threat-its-all-cephalon-ceo-baldinos-fault/]]></link>
		<description><![CDATA[Jon Leibowitz, chairman of the FTC, argued in a speech that eliminating patent settlements between brand-name and generic drug companies would save consumers $35 billion annually. Then he blamed Cephalon CEO Frank Baldino for paying $200 million to four challengers in return for an estimated $4 billion in extra sales....]]></description>
		<s:doctype><![CDATA[Blog posts]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_bnet.gif" type="image/gif" />
		<pubDate>Wed, 24 Jun 2009 12:00:38 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://resources.bnet.com/topic/ftc.html"><![CDATA[FTC]]></category>
		<category domain="http://resources.bnet.com/topic/sales+strategy.html"><![CDATA[Sales Strategy]]></category>
		<category domain="http://resources.bnet.com/topic/litigation.html"><![CDATA[Litigation]]></category>
		<category domain="http://resources.bnet.com/topic/sales+force+management.html"><![CDATA[Sales Force Management]]></category>
		<category domain="http://resources.bnet.com/topic/sales.html"><![CDATA[Sales]]></category>
		<category domain="http://resources.bnet.com/topic/business+operations.html"><![CDATA[Business Operations]]></category>
		<category domain="http://resources.bnet.com/topic/jim+edwards.html"><![CDATA[Jim Edwards]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="tickers">CEPH</category>
	</item>
	<item>
		<title><![CDATA[Cephalon Chugs Along, Despite Fentora, Provigil Setbacks]]></title>
		<link><![CDATA[http://dw.com.com/redir?destUrl=http%3A%2F%2Fseekingalpha.com%2Farticle%2F143478-cephalon-chugs-along-despite-fentora-provigil-setbacks%3Fsource%3Dbnet&siteid=23&tag=seekingalpha]]></link>
		<description><![CDATA[Zacks.com submits:   By Jason Napodano, CFA Cephalon CEPH shares are currently trading at 9.6x our 2009 EPS estimate of $5.90 (fully-diluted). The shares declined significantly early last year on concerns regarding the growth prospects of Provigil and Fentora. by Zacks.com]]></description>
		<s:doctype><![CDATA[External links]]></s:doctype>
		<enclosure url="http://i.bnet.com/images/200803/icon_seekingalpha.gif" type="image/gif" />
		<pubDate>Tue, 16 Jun 2009 05:57:38 -0700</pubDate>
		<category domain="http://resources.bnet.com/topic/healthcare.html"><![CDATA[Healthcare]]></category>
		<category domain="http://resources.bnet.com/topic/zacks.com.html"><![CDATA[Zacks.com]]></category>
		<category domain="http://resources.bnet.com/topic/cephalon+inc..html"><![CDATA[Cephalon Inc.]]></category>
		<category domain="http://rss.financialcontent.com/stocksymbol">CEPH</category>
		<category domain="tickers">CEPH</category>
	</item>
</channel>
</rss>
